Intravitreal Injection

KOLOA, Hawaii — Retina specialists have a lot of options when it comes to intravitreal injection procedures, according to a speaker at Retina 2025.

4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.

The first patient underwent dosing in the phase 3 LUCIA clinical trial of Duravyu for wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.

NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases.

BARCELONA, Spain — Adopting specific treatment regimens, reducing patient and staff travel, and limiting the use of unnecessary personal protective equipment can help improve the carbon footprint of intravitreal injections.

In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses 36-month real-world data on the Yutiq implant for the treatment of chronic noninfectious uveitis.

Intravitreal injections have a large environmental impact, estimated to be around 210 million kg of CO2 equivalent per year in the U.S. alone, according to a presenter at the American Society of Retina Specialists annual meeting.

One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with wet age-related macular degeneration, according to a study presented at the American Society of Retina Specialists meeting.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Anat Loewenstein, MD, of Tel Aviv Medical Center in Israel, discusses Axpaxli for the treatment of neovascular age-related macular degeneration.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher S. Dhoot, MD, discusses 52-week phase 1 data for Axpaxli for the treatment of neovascular age-related macular degeneration.